Luly Jay R.'s Form 4 filing
Enanta Pharmaceuticals Inc (ENTA) · filed Dec 16, 2022
- Accession no.
- 0001062993-22-024037
- Filed
- Dec 16, 2022
- Trade date
- Dec 16, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.34M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Luly Jay R.CIK 0001571211 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 16, 2022 | Common Stock | MOption exerciseAcquired | +16,149 | $14.18 | +$228,992.82 | 789,954 | Direct | |
| Dec 16, 2022 | Common Stock | MOption exerciseAcquired | +13,851 | $14.00 | +$193,914 | 803,805 | Direct | |
| Dec 16, 2022 | Common Stock | SSaleDisposed | −7,800 | $43.59 | −$340,002 | 796,005 | Direct | |
| Dec 16, 2022 | Common Stock | SSaleDisposed | −8,597 | $44.54 | −$382,910.38 | 787,408 | Direct | |
| Dec 16, 2022 | Common Stock | SSaleDisposed | −13,603 | $45.49 | −$618,800.47 | 773,805 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 16, 2022 | Common Stock | MOption exerciseDisposed | −16,149 | $0.00 | $0 | 0 | Direct | |
| Dec 16, 2022 | Common Stock | MOption exerciseDisposed | −13,851 | $0.00 | $0 | 27,912 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.